Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Shares Outstanding (2016 - 2025)

ImmunityBio (IBRX) has disclosed Shares Outstanding for 2 consecutive years, with $82.0 million as the latest value for Q4 2016.

  • On a quarterly basis, Shares Outstanding changed N/A to $82.0 million in Q4 2016 year-over-year; TTM through Dec 2016 was $82.0 million, a N/A change, with the full-year FY2016 number at $82.0 million, changed N/A from a year prior.
  • Shares Outstanding was $82.0 million for Q4 2016 at ImmunityBio, up from $69.6 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $82.0 million in Q4 2016 to a low of $69.6 million in Q2 2015.